NasdaqGS:CGONBiotechs
How Investors May Respond To CG Oncology (CGON) Leadership Transition Amid Rising Revenue and Expanding Losses
On November 14, 2025, CG Oncology reported its third quarter and nine-month financial results, highlighting a significant year-over-year increase in revenue to US$1.67 million and US$1.72 million respectively, but with a wider net loss for both periods.
In addition, the company announced the appointment of Jim DeTore as interim principal financial and accounting officer effective November 17, signifying a transition in leadership amid financial changes.
We'll examine how the arrival of a new...